Portable Screening Test For Tuberculosis
A Key Requirement To Eradicate a Global Pandemic
EpiLAB's state of the art technology helps health organisation that want to fight tuberculosis by improving the rate of diagnosis in developing countries and reducing the number of new infections and victims.
Tuberculosis In Figures
10 Million New Cases Each Year
Each year, 10 million people contract tuberculosis. One-third of these new cases, representing about 3 million individuals, are not detected and remain unknown to health organisations. As a result, patients are not receiving appropriate treatment, thereby allowing for ongoing disease transmission.
3 Million Undetected Cases
Eighty percents of new yearly cases emerge in developing countries that lack resources to implement successful diagnosis campaigns. Existing tests are not adapted to the needs of those countries.
3 in10 people with tuberculosis
are not diagnosed or treated
1.5 Million Victims
Despite being a preventable and curable disease, 1.5 million people die from tuberculosis each year because their diagnosis is “missed,” making it the world’s top infectious disease killer.
The main reason of this underdiagnosis are:
-
Infrastructure (labs) required : most of the population does not have easy access to the few existing infrastructures
-
Medically qualified staff required
-
Testing is expensive.
-
Available tests are unquantifiable and lack sensitivity
EpiLAB Screening Test
The answer to underdiagnosis of Tuberculosis in developing countries
Portable
No infrastructure needed
Affordable
Adapted to affected countries
Consumables
Reusable reader
x 1000
Matches WHO's demand
Easy To Use
No qualification needed
Sensitive
Competitive with existing tests
How We Do It?
We leverage a patented tuberculosis detection method using specific enzymatic reactions coupled with electrochemical detection.
To learn more about EpiLAB patented technology send us a message by clicking the button below.
They Support Us
Get In Touch
NEWS
EpiLAB in Les Echos
February 2021
Article in Les Echos, looking back at the beginnings of the start-up and the collaboration with SATT Sayens. Sayens has overseen the maturation of the innovation based on the electrochemical detection of tuberculosis, and now becomes a minor shareholder of the company to help deploy this rapid diagnostic kit on a global scale.
EpiLAB is labeled DeepTech Pioneer by Hello Tomorrow
November 2020
Hello tomorrow is a mission-driven global organisation that aims to accelerate the transfer of deep technologies to solve some of our most pressing industrial, environmental and societal challenges. For its global summit, they selects start-ups that are game-changers developing cutting-edge technology to bring positive change to our planet, society and industries : DeepTech Pioneers.
Participation in two challenges
October 2020
EpilAB wins the Prix de l'ingénierie du futur by SYNTEC (https://www.youtube.com/watch?v=k3a0yH9jWDg&ab_channel=Concepteursd%27Avenirs) and reaches the final of the challenge of Centrale Schools
NEWS
Meeting Frédérique Vidal, at Viva Technology event
June 2021
Viva technology, Europe's biggest startup and tech event, was organised in june 2021 in Paris. Epilab had the opportunity to present its solution on a stand and meet several potential partners.
Special thanks to Frederic Vidal, Minister of Higher Education, Research and Innovation, to whom we presented the EpiLAB solution.
Interview with Epilab at France biotech
June 2021
France Biotech is the French trade association of biotechnology companies. Its primary mission is to support the development of this industry in France.
Epilab was the subject of the 5th episode of its "Pépites Healthtech" series where France Biotech present promising start-ups.
EpiLAB in Challenges
March 2021
Thanks to Challenges for selecting EpiLAB in the 100 startups to invest in in 2021. EpiLAB is raising 1 million € to fund the development of screening kit, and scientific R&D, in order to deploy the first tests as soon as possible.
B Smart - EpiLAB
March 2021
Thanks to B SMART for talking about us, and introducing EpiLAB test to their viewers.
EpiLAB in Les Echos
February 2021
Article in Les Echos, looking back at the beginnings of the start-up and the collaboration with SATT Sayens. Sayens has overseen the maturation of the innovation based on the electrochemical detection of tuberculosis, and now becomes a minor shareholder of the company to help deploy this rapid diagnostic kit on a global scale.
EpiLAB joins La French Tech Paris Saclay community
February 2021
French Tech Paris-Saclay represents the interests of a community of start-ups, scaleups and project leaders in the Paris-Saclay, Yvelines and Essonne area.